Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials.

Nauman G, Gray JC, Parkinson R, Levine M, Paller CJ.

Antioxidants (Basel). 2018 Jul 12;7(7). pii: E89. doi: 10.3390/antiox7070089. Review.

2.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

3.

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.

Xi D, Bao T, Chen Q, Chen S, Cheng YC, Cullen J, Frank DA, Friedberg JW, Kronish I, Lee JE, Levine M, Li P, Li S, Lu W, Mao JJ, O'Keefe S, Rubinstein L, Shah MA, Standish L, Paller CJ, Chu E.

J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx003.

4.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA.

Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7.

PMID:
29113986
5.

Risk factors for metastatic prostate cancer: A sentinel event case series.

Paller CJ, Cole AP, Partin AW, Carducci MA, Kanarek NF.

Prostate. 2017 May;77(13):1366-1372. doi: 10.1002/pros.23396. Epub 2017 Aug 8.

6.

A review of pomegranate in prostate cancer.

Paller CJ, Pantuck A, Carducci MA.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):265-270. doi: 10.1038/pcan.2017.19. Epub 2017 Apr 25. Review.

7.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.

J Clin Oncol. 2017 Jul 1;35(19):2149-2156. doi: 10.1200/JCO.2016.70.1961. Epub 2017 Apr 6.

8.

Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.

Markowski MC, Imus P, Wright JL, Schottenstein D, Paller CJ.

Clin Genitourin Cancer. 2017 Oct;15(5):e839-e842. doi: 10.1016/j.clgc.2017.02.001. Epub 2017 Feb 27. No abstract available.

9.

Detection fidelity of AR mutations in plasma derived cell-free DNA.

Goldstein A, Toro PV, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ.

Oncotarget. 2017 Feb 28;8(9):15651-15662. doi: 10.18632/oncotarget.14926.

10.

Challenges of conducting clinical trials of natural products to combat cancer.

Paller CJ, Denmeade SR, Carducci MA.

Clin Adv Hematol Oncol. 2016 Jun;14(6):447-55. Review.

PMID:
27379814
11.

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study.

Ball MW, Gorin MA, Guner G, Pierorazio PM, Netto G, Paller CJ, Hammers HJ, Diaz LA, Allaf ME.

Clin Genitourin Cancer. 2016 Oct;14(5):e515-e520. doi: 10.1016/j.clgc.2016.03.019. Epub 2016 Mar 24. No abstract available.

12.

Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.

van Die MD, Bone KM, Emery J, Williams SG, Pirotta MV, Paller CJ.

BJU Int. 2016 Apr;117 Suppl 4:17-34. doi: 10.1111/bju.13361. Epub 2016 Feb 22. Review.

13.

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA.

Prostate. 2016 Apr;76(5):512-20. doi: 10.1002/pros.23141. Epub 2015 Dec 22.

PMID:
26689606
14.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

15.

Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital.

Markowski MC, Eisenberger MA, Zahurak M, Epstein JI, Paller CJ.

Urology. 2015 Sep;86(3):539-43. doi: 10.1016/j.urology.2015.06.011. Epub 2015 Jun 28.

16.

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.

Ann Oncol. 2015 Sep;26(9):1859-65. doi: 10.1093/annonc/mdv282. Epub 2015 Jun 27.

17.

Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status.

Paller CJ, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS.

Prostate. 2015 Sep;75(13):1376-83. doi: 10.1002/pros.23018. Epub 2015 Jun 5.

18.

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.

Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA.

Prostate. 2015 Oct;75(14):1518-25. doi: 10.1002/pros.23024. Epub 2015 May 27.

19.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

20.

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.

Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874. Epub 2014 Aug 31.

21.

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.

Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves S, Ellis LM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ.

Clin Cancer Res. 2014 Aug 15;20(16):4210-7. doi: 10.1158/1078-0432.CCR-14-0521. Review.

22.

Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.

Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK.

Cancer Med. 2014 Oct;3(5):1322-35. doi: 10.1002/cam4.289. Epub 2014 Jul 3.

23.

Management of patients with biochemical recurrence after local therapy for prostate cancer.

Paller CJ, Antonarakis ES, Eisenberger MA, Carducci MA.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1205-19, viii. doi: 10.1016/j.hoc.2013.08.005. Epub 2013 Sep 18. Review.

24.

The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.

Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL.

Prostate Cancer Prostatic Dis. 2014 Mar;17(1):28-33. doi: 10.1038/pcan.2013.40. Epub 2013 Oct 8.

25.
26.

Management of bone metastases in refractory prostate cancer--role of denosumab.

Paller CJ, Carducci MA, Philips GK.

Clin Interv Aging. 2012;7:363-72. doi: 10.2147/CIA.S27930. Epub 2012 Sep 17. Review.

27.

Finasteride and prostate cancer: a commentary.

Paller CJ, Smith TJ.

Oncologist. 2012;17(7):888-90. doi: 10.1634/theoncologist.2012-0165. Epub 2012 Jun 20. No abstract available.

28.

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.

29.

Association between sex steroid hormones and hematocrit in a nationally representative sample of men.

Paller CJ, Shiels MS, Rohrmann S, Menke A, Rifai N, Nelson WG, Platz EA, Dobs AS.

J Androl. 2012 Nov-Dec;33(6):1332-41. doi: 10.2164/jandrol.111.015651. Epub 2012 May 17.

30.

Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.

Paller CJ, Antonarakis ES.

Hum Vaccin Immunother. 2012 Apr;8(4):509-19. doi: 10.4161/hv.18860. Epub 2012 Apr 1. Review.

PMID:
22336881
31.

Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer.

Paller CJ, Antonarakis ES.

Drug Des Devel Ther. 2011 Mar 10;5:117-24. doi: 10.2147/DDDT.S13029. Review. Erratum in: Drug Des Devel Ther. 2011;5:183.

32.

Youth has no age: cancer treatment for older Americans.

Paller CJ, Rudin CM.

Oncology (Williston Park). 2010 Nov 15;24(12):1114, 1118, 1120. No abstract available.

33.

Sex-based differences in pain perception and treatment.

Paller CJ, Campbell CM, Edwards RR, Dobs AS.

Pain Med. 2009 Mar;10(2):289-99. doi: 10.1111/j.1526-4637.2008.00558.x. Epub 2009 Jan 16. Review.

34.

Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men.

Paller CJ, Shiels MS, Rohrmann S, Basaria S, Rifai N, Nelson W, Platz EA, Dobs A.

Clin Endocrinol (Oxf). 2009 Jan;70(1):26-34. doi: 10.1111/j.1365-2265.2008.03300.x. Epub 2008 May 14.

35.

High glucose blocks the effects of estradiol on human vascular cell growth: differential interaction with estradiol and raloxifene.

Somjen D, Paller CJ, Gayer B, Kohen F, Knoll E, Stern N.

J Steroid Biochem Mol Biol. 2004 Jan;88(1):101-10.

Supplemental Content

Loading ...
Support Center